Top Investing Today
  • Investing
  • Politics
  • Stock
  • Economy
  • Editor’s Pick
  • Investing
  • Politics
  • Stock
  • Economy
  • Editor’s Pick
No Result
View All Result
Top Investing Today
No Result
View All Result
Home Editor's Pick

Humacyte (HUMA) stock price is pumping but 1 key risk remain

BoldThemes by BoldThemes
May 30, 2024
in Editor's Pick
0
Humacyte (HUMA) stock price is pumping but 1 key risk remain
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Humacyte (NASDAQ: HUMA) stock price has surged hard since I wrote about it in April. It soared to a high of $9.35 on Thursday and is now trading at its highest point since December 2021. It has risen for seven straight weeks and is up by almost 370% from its lowest swing this year.

The initial reason for the surge was that Senator Tommy Turbeville of Alabama acquired it in March. This was notable since the senator sits on the influential Senate Armed Services Committee and the company is researching on products that will be used by the Department of Defense (DoD).

Precisely, Humacyte is working on a solution that will introduce implantable bioengineered human tissues. The goal is to address numerous diseases, injuries, and chronic diseases. Its products are being tested in the ongoing war between Ukraine and Russia. 

Humacyte stock chart

Humacyte has achieved a lot in the past few months. For example, it received a FDA approval of its Biological License Application (BLA) and completed its Budget Impact Model that highlighted the value its Human Acellular Vessel (HAV) products would bring to its clients. 

Analysts are upbeat about the company. In a recent note, analysts at Cowen noted that HAV could be approved by August 10th of this year. If this happens, the company could start commercial launch by the end of the year. The analyst noted the following:

“Humacyte is poised to gain significant share for surgical procedures requiring vascular grafts, including reconstruction due to trauma, vascular access for dialysis patients, peripheral arterial disease repair, and, eventually, coronary artery bypass grafts.”

If Humacyte is successful, it has two options available. It could decide to do the commercialization itself, which is often an expensive endeavor. Alternatively, it could receive an acquisition offer, from some of the top players in the wound care industry like Smith & Nephew and ConvaTec.

Humacyte has also soared because of its growing popularity in social media platforms like Reddit and StockTwits. It has been one of the most trending stocks in these platforms recently, attracting a sense of FOMO.A likely risk that Humacyte investors face is a potential dilution now that the stock has gone parabolic. It ended the last quarter with over $115 million in cash and short-term investments and had a net loss of over $31.9 million during the quarter.

The post Humacyte (HUMA) stock price is pumping but 1 key risk remain appeared first on Invezz

Previous Post

China Advances IoT Ambitions with Successful Sea Launch of Four Satellites

Next Post

What made Smart for Life stock skyrocket on Thursday?

BoldThemes

BoldThemes

Next Post
What made Smart for Life stock skyrocket on Thursday?

What made Smart for Life stock skyrocket on Thursday?

  • Trending
  • Comments
  • Latest
The Connectivity Standards Alliance Product Security Working Group Launches the IoT Device Security Specification 1.0

The Connectivity Standards Alliance Product Security Working Group Launches the IoT Device Security Specification 1.0

March 19, 2024
Israel says UN ‘deceiving’ world over aid delays to Gaza

Israel says UN ‘deceiving’ world over aid delays to Gaza

March 28, 2024
Gold and Silver Set to Smash Records: Could 2024 Be Their Biggest Year Yet?

Gold and Silver Set to Smash Records: Could 2024 Be Their Biggest Year Yet?

May 17, 2024
Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

February 6, 2024

Senate Republicans ram Trump’s ‘big, beautiful bill’ through key test vote

0
Amid growing criticism of Biden foreign policy, experts credit wins while leaving room for improvement

Amid growing criticism of Biden foreign policy, experts credit wins while leaving room for improvement

0
Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

0
Precision Manufacturing For Sensitive Equipment With CNC Machining

Precision Manufacturing For Sensitive Equipment With CNC Machining

0

Senate Republicans ram Trump’s ‘big, beautiful bill’ through key test vote

June 29, 2025

Chief Justice Roberts sounds alarm on dangerous rhetoric aimed at judges from politicians

June 29, 2025

Rubio condemns Iran’s ‘unacceptable’ threats against IAEA director

June 28, 2025

Schumer to force Senate reading of Trump’s entire ‘big, beautiful bill’

June 28, 2025
Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Recent News

    Senate Republicans ram Trump’s ‘big, beautiful bill’ through key test vote

    June 29, 2025

    Chief Justice Roberts sounds alarm on dangerous rhetoric aimed at judges from politicians

    June 29, 2025

    Rubio condemns Iran’s ‘unacceptable’ threats against IAEA director

    June 28, 2025

    Schumer to force Senate reading of Trump’s entire ‘big, beautiful bill’

    June 28, 2025
    • About Us
    • Privacy Policy
    • Terms & Conditions
    • Contact

    Copyright © 2024 Topinvestingtoday.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Politics
    • Stock
    • Economy
    • Editor’s Pick

    Copyright © 2024 Topinvestingtoday.com. All Rights Reserved.